Australia's most trusted
source of pharma news
Wednesday, 15 January 2025
Posted 2 August 2024 AM
Novo Nordisk will finally launch its blockbuster obesity drug Wegovy in Australia on Monday via private prescription.
Wegovy 2.4mg will be available for chronic weight management for those living with obesity, or overweight with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol, for use in addition to a reduced-energy diet and increased physical activity.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.